Microbix sues Novartis for patent infringement in Europe

Canada-based Microbix has slapped Novartis ($NVS) with a lawsuit in Europe, where it says the Swiss pharma giant has infringed its patent on Virusmax--a technology used for increasing virus yields in egg-based vaccine manufacturing. The latest litigation is part of an ongoing legal tussle between the two companies: According to Microbix, Novartis has previously challenged its IP shield and is appealing a January decision from the European Patent Office that Virusmax is a novel, useful and nonobvious invention. A Novartis spokeswoman told FierceVaccines the Basel-based drugmaker could not comment. Release

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan